share_log

Anebulo Pharmaceuticals Analyst Ratings

Anebulo Pharmaceuticals Analyst Ratings

Anebulo Pharmicals 分析師評級
Benzinga ·  2023/09/18 18:32
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/18/2023 87.5% HC Wainwright & Co. → $6 Initiates Coverage On → Buy
05/18/2023 150% Benchmark → $8 Reiterates Speculative Buy → Speculative Buy
02/14/2023 150% Benchmark $10 → $8 Maintains Speculative Buy
07/27/2022 87.5% Ladenburg Thalmann → $6 Initiates Coverage On → Buy
05/25/2021 368.75% Benchmark → $15 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/18/2023 87.5% HC Wainwright公司 →$6 開始承保 →購買
2023年05月18日 150% 基準 →$8 重申 投機性買入→投機性買入
02/14/2023 150% 基準 $10→$8 維護 投機性購買
07/27/2022 87.5% 拉登堡·塔爾曼 →$6 開始承保 →購買
2021/05/25 368.75% 基準 →$15 開始承保 →購買

What is the target price for Anebulo Pharmaceuticals (ANEB)?

AneBulo製藥公司(ANEB)的目標價是多少？

The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $6.00 expecting ANEB to rise to within 12 months (a possible 87.50% upside). 3 analyst firms have reported ratings in the last year.

安妮寶製藥(納斯達克：ANEB)的最新目標價是由HC Wainwright&Co.於2023年9月18日報道的。這家分析公司將目標價定為6.00美元，預計ANEB將在12個月內上漲(可能上漲87.50%)。3家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?

分析師對安妮寶製藥(ANEB)的最新評級是多少？

The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by HC Wainwright & Co., and Anebulo Pharmaceuticals initiated their buy rating.

納斯達克(Sequoia Capital：ANEB)的最新分析師評級由HC Wainwright&Co.提供，AneBulo PharmPharmticals啟動了買入評級。

When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?

AneBulo PharmPharmticals(ANEB)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與AneBulo製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。AneBulo製藥的上一次評級是在2023年9月18日提交的，所以你應該預計下一次評級將在2024年9月18日左右的某個時候公佈。

Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?

分析師對AneBulo製藥公司(ANEB)的評級正確嗎？

While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a initiated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.20, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的AneBulo PharmPharmticals(ANEB)評級是以0.00美元至6.00美元的目標價啟動的。AneBulo PharmPharmticals(ANEB)目前的交易價格為3.20美元，在分析師的預測範圍內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論